India’s Pharmaceutical Exports Surge to $30.47 Billion
India’s pharmaceutical exports reached an impressive USD 30.47 billion in the fiscal year 2024–25, marking a 9.4 percent increase from the previous year. This growth is attributed to India’s robust manufacturing capabilities and its expanding global footprint, as highlighted by Commerce Secretary Shri Rajesh Agrawal during a one-day Regional Chintan Shivir focused on Pharmaceutical Exports in Chandigarh.
The domestic pharmaceutical market in India is also thriving, currently estimated at around USD 60 billion. Shri Agrawal projected that this market could potentially double to nearly USD 130 billion by 2030, underscoring the sector’s vast potential for innovation and scale.
Catalyzing Collaboration for Export Growth
This initiative was organized by India’s Department of Commerce in collaboration with the Pharmaceutical Export Promotion Council of India (PHARMEXCIL). The event brought together key stakeholders, including policymakers, regulators, industry representatives, exporters from MSMEs, Indian missions abroad, and technical experts, to discuss pivotal issues impacting India’s pharmaceutical export landscape.
Shri Agrawal emphasized that India stands as the world’s third-largest producer of pharmaceuticals by volume and ranks fourteenth by value, boasting over 3,000 manufacturing companies and 10,500 production units that cater to more than 60,000 generic brands across various therapeutic categories.
Global Reach and Future Opportunities
Indian pharmaceuticals are exported to over 200 markets worldwide, with more than 60 percent directed toward markets with stringent regulatory standards. The United States alone accounts for roughly 34 percent while Europe represents approximately 19 percent of these exports. These strengths, combined with India’s reputation as a reliable supplier of high-quality and affordable medicines, provide a solid foundation for future export growth.
Discussions during the Chintan Shivir centered on enhancing awareness among exporters—particularly MSMEs—about the changing international trade landscape. Topics included identifying non-tariff barriers, regulatory challenges, and fostering regulatory cooperation for quicker approvals. The aim was to strengthen India’s life sciences innovation ecosystem, which encompasses areas like research and development, clinical trials, vaccines, and biologics.
Strengthening Trade Policies
Participants also learned about recent progress in India’s international trade agreements, specifically the India–UK Comprehensive Economic and Trade Agreement (CETA) and the India–EFTA Trade and Economic Partnership Agreement (TEPA). These agreements, highlighted for their zero-tariff provisions, are poised to enhance the competitiveness of Indian generic medicines while also creating investment and job opportunities.
Special technical sessions addressed vital topics like Antimicrobial Resistance (AMR), skilled workforce development, updates in Foreign Trade Policy, and revisions to the Good Manufacturing Practices (GMP). Experts from various organizations shared valuable insights into regulatory readiness, quality management systems, and digital compliance strategies.
A Vision for the Future
The day concluded with an interactive session focusing on the revised GMP framework. These discussions reaffirmed the government’s commitment to regulatory enhancement, trade facilitation, and close collaboration with the pharmaceutical industry. Together, these efforts are aimed at boosting India’s export competitiveness and solidifying its global position in the pharmaceutical sector.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
Follow Us on Twitter, Instagram, Facebook, & LinkedIn
